Cargando…

A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?

Based on clinical trials of systemic treatments in adults with moderate-to-severe atopic dermatitis (AD) reported between 2014 and 2023, we used linear regression to investigate relationships between baseline Eczema Area and Severity Index (EASI) scores and (1) study start date, (2) EASI response, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silverberg, Jonathan I., Ho, Selwyn, Collazo, Raúl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689679/ https://www.ncbi.nlm.nih.gov/pubmed/37917285 http://dx.doi.org/10.1007/s13555-023-01052-5

Ejemplares similares

The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis
por: Simpson, Eric L., et al.
Publicado: (2022)

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Associations between atopic dermatitis and other disorders
por: Silverberg, Jonathan I.
Publicado: (2018)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Phenotypic differences of atopic dermatitis stratified by age
por: Chatrath, Sheena, et al.
Publicado: (2022)

Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children
por: Chovatiya, Raj, et al.
Publicado: (2019)

Dermatology for the internist: optimal diagnosis and management of atopic dermatitis
por: Narla, Shanthi, et al.
Publicado: (2021)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Food allergy testing in atopic dermatitis
por: Ramírez-Marín, Hassiel A., et al.
Publicado: (2022)

Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial
por: Weyne, Jonathan, et al.
Publicado: (2020)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Clinical Features of Adult/Adolescent Atopic Dermatitis and Chinese Criteria for Atopic Dermatitis
por: Liu, Ping, et al.
Publicado: (2016)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials
por: Penton, Hannah, et al.
Publicado: (2023)

Comparative Efficacy of Targeted Systemic Therapies for Moderate-to-Severe Atopic Dermatitis without Topical Corticosteroids: An Updated Network Meta-analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Atopic Dermatitis: Epidemiology and Clinical Phenotypes
por: Raimondo, Annunziata, et al.
Publicado: (2021)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
por: Simpson, Eric L., et al.
Publicado: (2021)

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
por: Ayasse, Marissa, et al.
Publicado: (2020)

Clinical trials of antibody drugs in the treatments of atopic dermatitis
por: Zhou, Guihao, et al.
Publicado: (2023)

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
por: SILVERBERG, Jonathan I., et al.
Publicado: (2020)

Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study
por: Thaçi, Diamant, et al.
Publicado: (2022)

Atopic dermatitis is not associated with SARS-CoV-2 outcomes
por: Rakita, Uros, et al.
Publicado: (2021)

Clinical Efficacy of a Digital Intervention for Patients with Atopic Dermatitis: a Prospective Single-Center Study
por: Gudmundsdóttir, Sigrídur Lára, et al.
Publicado: (2022)

EPIDEMIOLOGY AND CLINICAL FEATURES OF ATOPIC DERMATITIS IN INDIA
por: Kanwar, Amrinder J, et al.
Publicado: (2011)

Prevalence and Clinical Features of Atopic Dermatitis in China
por: Wang, Xin, et al.
Publicado: (2016)

Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib
por: Owji, Shayan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l3r9houib87l9r2t34gc6lgln3